Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2006
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment included in reporting. The company focuses on the development, manufacture, and marketing of pharmaceutical products for human and animal health.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $3,714.7 | $3,497.4 |
| Gross Margin | 78.3% | 75.4% |
| Net Income | $834.8 | $736.6 |
| Earnings Per Share (Diluted) | $0.77 | $0.68 |
| Cash and Cash Equivalents | $2,458.3 | $5,607.7 (Q1 2005) |
| Total Debt | $6,348.5 | $6,498.2 (Dec 31, 2005) |
| Operating Cash Flow | $254.5 | $804.8 |
Debt and Liquidity: Total debt decreased to $6.35 billion from $6.50 billion at year-end 2005. Cash and cash equivalents stood at $2.46 billion, with short-term investments of $2.05 billion. The company maintains a commercial paper program backed by $1.23 billion in unused committed bank credit facilities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% to $3.71 billion, driven by the collective growth of Cymbalta and other newer products. U.S. sales rose 10%, while international sales increased 2%.
- Profitability: Net income increased 13% to $834.8 million. Gross margins improved by 2.9 percentage points to 78.3% due to increased production volume, favorable foreign exchange rates, and product mix.
- Operating Expenses: Total operating expenses increased 5%. Research and development (R&D) expenses rose 5% to $740.8 million, and marketing and administrative expenses increased 5% to $1.14 billion.
- Cash Flow: Net cash provided by operating activities decreased significantly to $254.5 million from $804.8 million in the prior year, largely due to changes in operating assets and liabilities.
- Product Performance:
- Cymbalta: Sales surged 118% to $233.3 million.
- Forteo: Sales grew 90% to $127.1 million.
- Zyprexa: Sales declined 3% to $1,007.4 million due to lower demand and generic patent litigation pressures.
- Humulin: Sales dropped 15% to $218.5 million due to competitive pressures.
Guidance, Outlook, and Risks
Management Guidance (2006)
- EPS: Expected to be in the range of $3.10 to $3.20 for the full year.
- Sales Growth: Anticipated to grow 7% to 9%.
- Gross Margins: Expected to improve modestly compared to 2005.
- Operating Expenses: Expected to grow in the mid-single digits.
- Other Income: Expected to contribute $175 million to $275 million.
- Capital Expenditures: Expected to be flat at approximately $1.4 billion.
Key Risks and Contingencies
- Zyprexa Litigation: The company faces significant product liability lawsuits alleging Zyprexa causes diabetes. While settlements covering approximately 10,500 claimants are in principle, approximately 800 lawsuits (4,700 claimants) remain. A $1.07 billion net pre-tax charge was recorded in Q2 2005 for these matters. Insurance carriers are disputing coverage.
- Patent Challenges: Generic manufacturers (Reddy, Teva, Barr, Sicor) are challenging patents for Zyprexa, Evista, and Gemzar. An appeal regarding Zyprexa patents was heard in April 2006; an unfavorable outcome could materially impact results.
- Government Investigations: The U.S. Attorney's office is investigating marketing practices for Zyprexa, Prozac, and others, including rebate agreements and Medicaid reporting. Outcomes could include fines or penalties.
- Regulatory Environment: Implementation of the Medicare Prescription Drug, Improvement and Modernization Act (MMA) and potential state-level importation schemes pose pricing pressures.
Investor Verification Checklist
- Zyprexa Settlement Status: Verify the finalization of the 10,500 claimant settlements and the status of remaining lawsuits.
- Patent Appeal Outcome: Monitor the Federal Circuit Court decision on the Zyprexa patent appeal.
- Insurance Recovery: Assess the likelihood of recovering litigation costs from insurance carriers given their defenses.
- Product Pipeline: Track the FDA review of Arxxant (ruboxistaurin mesylate) and the supplemental NDA for Evista.
- Actos Revenue Transition: Confirm the impact of the expiring U.S. marketing rights for Actos (September 2006) on future revenue streams.
- Government Investigation Resolution: Monitor developments in the U.S. Attorney's civil investigation regarding marketing practices.